Trial Profile
An open-label, randomised, single and repeat dose parallel group Phase I study to evaluate the pharmacokinetics of ST10 at three dosage levels in subjects with iron deficiency (with or without anaemia).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Ferric maltol (Primary)
- Indications Iron deficiency anaemia
- Focus Biomarker; Pharmacokinetics
- Sponsors Iron Therapeutics
- 20 Oct 2023 According to a Shield Therapeutics media release, abstract has been accepted for poster presentation presenting post-hoc analysis from this study at the National Association of Nurse Practitioners in Women's Health 26th Annual Women's Healthcare Conference taking place 29 Oct - 1 Nov in San Diego, California. by Dr Michael Cody M.D.
- 12 Apr 2016 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 27 Sep 2014 Status changed from recruiting to completed as reported by EudraCT record.